These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 20580045)

  • 1. Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer?
    Parker CC; Ampil F; Burton G; Li BD; Chu QD
    Surgery; 2010 Aug; 148(2):386-91. PubMed ID: 20580045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
    Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome.
    Flowers A; Chu QD; Panu L; Meschonat C; Caldito G; Lowery-Nordberg M; Li BD
    Surgery; 2009 Aug; 146(2):220-6. PubMed ID: 19628077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
    Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR
    J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical characteristics and prognosis of different subtypes of breast cancer].
    Yuan ZY; Wang SS; Zhu MQ; Zheng L; Luo WB; Zhou ZM; Guan ZZ
    Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):456-61. PubMed ID: 19024523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is conservative surgery a good option for patients with "triple negative" breast cancer?
    Martinez-Ramos D; Escrig-Sos J; Torrella-Ramos A; Alcalde-Sanchez M; Salvador-Sanchis JL
    Breast; 2012 Jun; 21(3):401-5. PubMed ID: 22579462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.
    Millar EK; Graham PH; O'Toole SA; McNeil CM; Browne L; Morey AL; Eggleton S; Beretov J; Theocharous C; Capp A; Nasser E; Kearsley JH; Delaney G; Papadatos G; Fox C; Sutherland RL
    J Clin Oncol; 2009 Oct; 27(28):4701-8. PubMed ID: 19720911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of CXCR4 in primary tumor of patients with HER-2 negative breast cancer was predictive of a poor disease-free survival: a validation study.
    Mizell J; Smith M; Li BD; Ampil F; Chu QD
    Ann Surg Oncol; 2009 Oct; 16(10):2711-6. PubMed ID: 19593633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM; Zhang BN; Xuan LX; Zhao P
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial.
    Poggi MM; Danforth DN; Sciuto LC; Smith SL; Steinberg SM; Liewehr DJ; Menard C; Lippman ME; Lichter AS; Altemus RM
    Cancer; 2003 Aug; 98(4):697-702. PubMed ID: 12910512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.
    Peterson DJ; Truong PT; Sadek BT; Alexander CS; Wiksyk B; Shenouda M; Raad RA; Taghian AG
    Ann Surg Oncol; 2014 Oct; 21(11):3490-6. PubMed ID: 24841346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy.
    Margalit DN; Sreedhara M; Chen YH; Catalano PJ; Nguyen PL; Golshan M; Overmoyer BA; Harris JR; Brock JE
    Ann Surg Oncol; 2013 Mar; 20(3):811-8. PubMed ID: 22956068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bcl-2 expression predicts local relapse for early-stage breast cancer receiving conserving surgery and radiotherapy.
    Yang Q; Moran MS; Haffty BG
    Breast Cancer Res Treat; 2009 May; 115(2):343-8. PubMed ID: 18516673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
    J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast-conserving surgery for T3/T4 breast cancer: an analysis of 196 patients.
    Fitzal F; Riedl O; Wutzl L; Draxler W; Rudas M; Pluschnig U; Handl-Zeller L; Dubsky P; Bachleitner-Hofmann T; Steger G; Jakesz R; Gnant M
    Breast Cancer Res Treat; 2007 May; 103(1):45-52. PubMed ID: 17417725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].
    Fan Y; Guan Y; Zhao WH; Li Q; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):917-20. PubMed ID: 19173993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy.
    Vargas C; Kestin L; Go N; Krauss D; Chen P; Goldstein N; Martinez A; Vicini FA
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1514-21. PubMed ID: 16005576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy.
    Meric F; Mirza NQ; Vlastos G; Buchholz TA; Kuerer HM; Babiera GV; Singletary SE; Ross MI; Ames FC; Feig BW; Krishnamurthy S; Perkins GH; McNeese MD; Strom EA; Valero V; Hunt KK
    Cancer; 2003 Feb; 97(4):926-33. PubMed ID: 12569592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The negative effect of triple-negative breast cancer on outcome after breast-conserving therapy.
    Zaky SS; Lund M; May KA; Godette KD; Beitler JJ; Holmes LR; O'Regan RM; Yu ES; Yu DS; Landry JC
    Ann Surg Oncol; 2011 Oct; 18(10):2858-65. PubMed ID: 21442346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.